|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Babesia microti IgG, IgM Abs
Test CodeBABESMICABWRFL
CPT Codes
86753 (x2)
Includes
If Babesia microti (IgG) is Detected, then Babesia microti (IgG) Titer will be performed at an additional charge (CPT code(s): 86317).
If Babesia microti (IgM) is Detected, then Babesia microti (IgM) Titer will be performed at an additional charge (CPT code(s): 86317).
If Babesia microti (IgM) is Detected, then Babesia microti (IgM) Titer will be performed at an additional charge (CPT code(s): 86317).
Preferred Specimen
1 mL serum
Minimum Volume
0.2 mL
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 7 days
Frozen: 30 days
Refrigerated: 7 days
Frozen: 30 days
Methodology
Immunofluorescence Assay (IFA)
Setup Schedule
Set up: Mon, Wed-Sat; Report available 1-3 days
Reference Range
| Babesia microti Ab (IgG), Screen | Not Detected |
| Babesia microti Ab (IgM), Screen | Not Detected |
| Babesia microti Ab (IgG), Titer | <1:64 titer |
| Babesia microti Ab (IgM), Titer | <1:20 titer |
Clinical Significance
This test is for the detection of IgG and IgM antibodies against Babesia microti to aid in the diagnosis of Babesiosis. Babesiosis is a tickborne disease caused by transmission of the protozoa via the bite of an infected tick. B. microti is most common in the northern and upper Midwestern United States.
Testing for B. microti is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, and gastrointestinal symptoms. Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Anaplasma spp, Ehrlichia spp, and Borrelia burgdorferi (Lyme disease).
Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Other less common Babesia species in different geographic regions have been identified to infect humans, such as B. duncani and B. divergens. The extent of cross-reactivity between Babesia species is variable and may not be detected by this assay. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset.
References:
1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention.
2. Clinical Testing and Diagnosis for Ehrlichiosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html
3. Krause, PJ. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis. 2021 Jan 27;72(2):e49-e64. doi: 10.1093/cid/ ciaa1216.
Testing for B. microti is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, and gastrointestinal symptoms. Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Anaplasma spp, Ehrlichia spp, and Borrelia burgdorferi (Lyme disease).
Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Other less common Babesia species in different geographic regions have been identified to infect humans, such as B. duncani and B. divergens. The extent of cross-reactivity between Babesia species is variable and may not be detected by this assay. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset.
References:
1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention.
2. Clinical Testing and Diagnosis for Ehrlichiosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html
3. Krause, PJ. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis. 2021 Jan 27;72(2):e49-e64. doi: 10.1093/cid/ ciaa1216.
Performing Laboratory
| Quest Diagnostics Nichols Institute |
| 14225 Newbrook Drive |
| Chantilly, VA 20153 |
